Targeting MCL-1 in cancer: current status and perspectives

Myeloid leukemia 1 (MCL-1) is an antiapoptotic protein of the BCL-2 family that prevents apoptosis by binding to the pro-apoptotic BCL-2 proteins. Overexpression of MCL-1 is frequently observed in many tumor types and is closely associated with tumorigenesis, poor prognosis and drug resistance. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haolan, Guo, Ming, Wei, Hudie, Chen, Yongheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061042/
https://www.ncbi.nlm.nih.gov/pubmed/33883020
http://dx.doi.org/10.1186/s13045-021-01079-1
_version_ 1783681485204619264
author Wang, Haolan
Guo, Ming
Wei, Hudie
Chen, Yongheng
author_facet Wang, Haolan
Guo, Ming
Wei, Hudie
Chen, Yongheng
author_sort Wang, Haolan
collection PubMed
description Myeloid leukemia 1 (MCL-1) is an antiapoptotic protein of the BCL-2 family that prevents apoptosis by binding to the pro-apoptotic BCL-2 proteins. Overexpression of MCL-1 is frequently observed in many tumor types and is closely associated with tumorigenesis, poor prognosis and drug resistance. The central role of MCL-1 in regulating the mitochondrial apoptotic pathway makes it an attractive target for cancer therapy. Significant progress has been made with regard to MCL-1 inhibitors, some of which have entered clinical trials. Here, we discuss the mechanism by which MCL-1 regulates cancer cell apoptosis and review the progress related to MCL-1 small molecule inhibitors and their role in cancer therapy.
format Online
Article
Text
id pubmed-8061042
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80610422021-04-22 Targeting MCL-1 in cancer: current status and perspectives Wang, Haolan Guo, Ming Wei, Hudie Chen, Yongheng J Hematol Oncol Review Myeloid leukemia 1 (MCL-1) is an antiapoptotic protein of the BCL-2 family that prevents apoptosis by binding to the pro-apoptotic BCL-2 proteins. Overexpression of MCL-1 is frequently observed in many tumor types and is closely associated with tumorigenesis, poor prognosis and drug resistance. The central role of MCL-1 in regulating the mitochondrial apoptotic pathway makes it an attractive target for cancer therapy. Significant progress has been made with regard to MCL-1 inhibitors, some of which have entered clinical trials. Here, we discuss the mechanism by which MCL-1 regulates cancer cell apoptosis and review the progress related to MCL-1 small molecule inhibitors and their role in cancer therapy. BioMed Central 2021-04-21 /pmc/articles/PMC8061042/ /pubmed/33883020 http://dx.doi.org/10.1186/s13045-021-01079-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Wang, Haolan
Guo, Ming
Wei, Hudie
Chen, Yongheng
Targeting MCL-1 in cancer: current status and perspectives
title Targeting MCL-1 in cancer: current status and perspectives
title_full Targeting MCL-1 in cancer: current status and perspectives
title_fullStr Targeting MCL-1 in cancer: current status and perspectives
title_full_unstemmed Targeting MCL-1 in cancer: current status and perspectives
title_short Targeting MCL-1 in cancer: current status and perspectives
title_sort targeting mcl-1 in cancer: current status and perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061042/
https://www.ncbi.nlm.nih.gov/pubmed/33883020
http://dx.doi.org/10.1186/s13045-021-01079-1
work_keys_str_mv AT wanghaolan targetingmcl1incancercurrentstatusandperspectives
AT guoming targetingmcl1incancercurrentstatusandperspectives
AT weihudie targetingmcl1incancercurrentstatusandperspectives
AT chenyongheng targetingmcl1incancercurrentstatusandperspectives

Ejemplares similares